Table 3.

Clinical trials of other psoriasis treatment

Target	Drug	Dose	Efficacy		NCT number
RORγT	JTE-451	200 mg twice daily	PASI 75	11.8% at week 16	03832738
		400 mg twice daily		22.0% at week 16
	Mesenchymal stem cells	UMSC infusions once every 2 weeks	PASI 75	35.3% at month 6	03765957
			PASI 90	17.6% at month 6
AhR	Topical tapinarof	1% twice daily	PASI 75	65.0% at week 12	02564042
		1% once daily		56.0% at week 12
		0.5% twice daily		46.0% at week 12
		0.5% once daily		46.0% at week 12
		1% once daily	PASI 75	36.1% at week 12	03956355
			PASI 90	18.8% at week 12
			PASI 75	43.6% at week 12	03983980
			PASI 90	20.9% at week 12
S1PR1	Ponesimod	20 mg once daily	PASI 75	46.0% at week 16	01208090
			PASI 90	14.3% at week 16
		40 mg once daily	PASI 75	48.1% at week 16
			PASI 90	24.8% at week 16

AhR Aryl hydrocarbon receptor, S1PR1 S1P receptor 1, UMSC umbilical cord-derived mesenchymal stem cells, AhR aryl hydrocarbon receptor, S1PR1 sphingosine 1-phosphate receptor 1